Sarepta Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Sarepta Therapeutics, Inc.‘s stocks are currently a part of 312 hedge funds’ portfolios, which represents 87.81% of the total amount of its stocks outstanding. This makes up a total of 71.35M shares of Sarepta Therapeutics, Inc.. Compared to the previous quarter, the number grew by 0.49% or 347.23K shares more. As for the holding position changes, 28.85% (90) of current hedge fund investors increased the number of shares held, 37.82% (118) of current holders sold a part of the shares held, and 18.91% (59) closed the holdings completely. 53 hedge funds are new holders of Sarepta Therapeutics, Inc. stock in Q1 2022, it is 16.99% of total holders.
Hedge funds holding Sarepta Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 187 |
|---|---|
| Q3 2017 | 231 |
| Q4 2017 | 250 |
| Q1 2018 | 267 |
| Q2 2018 | 316 |
| Q3 2018 | 341 |
| Q4 2018 | 332 |
| Q1 2019 | 365 |
| Q2 2019 | 360 |
| Q3 2019 | 334 |
| Q4 2019 | 381 |
| Q1 2020 | 358 |
| Q2 2020 | 400 |
| Q3 2020 | 398 |
| Q4 2020 | 443 |
| Q1 2021 | 352 |
| Q2 2021 | 317 |
| Q3 2021 | 294 |
| Q4 2021 | 326 |
| Q1 2022 | 312 |
Hedge funds changes in Sarepta Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 34 | 76 | 48 | 21 | 8 |
|---|---|---|---|---|---|
| Q3 2017 | 68 | 104 | 34 | 23 | 2 |
| Q4 2017 | 55 | 77 | 91 | 31 | -4 |
| Q1 2018 | 54 | 74 | 110 | 34 | -5 |
| Q2 2018 | 87 | 74 | 124 | 37 | -6 |
| Q3 2018 | 71 | 115 | 106 | 45 | 4 |
| Q4 2018 | 53 | 125 | 110 | 59 | -15 |
| Q1 2019 | 71 | 141 | 113 | 36 | 4 |
| Q2 2019 | 56 | 125 | 116 | 58 | 5 |
| Q3 2019 | 71 | 127 | 100 | 95 | -59 |
| Q4 2019 | 100 | 115 | 110 | 47 | 9 |
| Q1 2020 | 51 | 121 | 126 | 68 | -8 |
| Q2 2020 | 89 | 127 | 126 | 45 | 13 |
| Q3 2020 | 52 | 133 | 140 | 52 | 21 |
| Q4 2020 | 88 | 123 | 159 | 41 | 32 |
| Q1 2021 | 59 | 135 | 115 | 144 | -101 |
| Q2 2021 | 51 | 101 | 121 | 82 | -38 |
| Q3 2021 | 41 | 111 | 99 | 61 | -18 |
| Q4 2021 | 66 | 114 | 95 | 32 | 19 |
| Q1 2022 | 53 | 90 | 118 | 59 | -8 |
Hedge funds changes in Sarepta Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 145,046,000 | 74,257,000 |
|---|---|---|
| Q3 2017 | 312,410,000 | 256,307,000 |
| Q4 2017 | 325,384,000 | 287,413,000 |
| Q1 2018 | 197,550,000 | 110,814,000 |
| Q2 2018 | 349,499,000 | 322,052,000 |
| Q3 2018 | 443,919,000 | 334,141,000 |
| Q4 2018 | 283,073,000 | 185,421,000 |
| Q1 2019 | 363,151,000 | 283,225,000 |
| Q2 2019 | 535,083,000 | 440,273,000 |
| Q3 2019 | 231,631,000 | 241,353,000 |
| Q4 2019 | 573,339,000 | 391,227,000 |
| Q1 2020 | 172,053,000 | 209,027,000 |
| Q2 2020 | 310,651,000 | 246,988,000 |
| Q3 2020 | 327,095,000 | 382,669,000 |
| Q4 2020 | 273,682,858,000 | 140,718,989,000 |
| Q1 2021 | 273,115,969,000 | 149,399,000 |
| Q2 2021 | 97,022,000 | 98,764,000 |
| Q3 2021 | 157,537,000 | 150,413,000 |
| Q4 2021 | 279,237,000 | 191,552,000 |
| Q1 2022 | 134,895,000 | 82,133,000 |